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Objective: To investigate clinical implications of ETS-1 expression in prostate cancer, 
particularly high-risk cases, including response to androgen deprivation therapy.  
Methods: The expression of ETS-1 was analyzed by immunohistochemical staining of 
paraffin-embedded prostate carcinoma tissue obtained by needle biopsy from 69 mostly 
advanced prostate cancer patients. ETS-1 expression was compared with 
clinicopathological characteristics of the 69 patients including 25 who underwent 
androgen-deprivation therapy as a primary treatment. 
Results: Prostate cancers with higher expression of ETS-1 were significantly more 
likely to be of high stage and high Gleason score (P<0.05). There was no significant 
association between ETS-1 expression and initial prostate-specific antigen (PSA) level. 
In the 25 patients treated by androgen deprivation therapy, the staining scores for ETS-1 
was significantly associated with rapid development of castration-resistant disease 
within 24 months (P<0.05), whereas Gleason sum or PSA level was not. 
Conclusions: Increased ETS-1 expression was associated with higher stage, higher 
Gleason score, and shorter time to castration-resistant progression. These data suggest 
that immunostaining for ETS-1 can be a molecular marker for predicting poor clinical 
outcome of prostate cancer patients, particularly with high-risk disease.  
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Prostate cancer (PC) is the most commonly diagnosed malignancy among
 
males in the 




 Patients with 
low-risk localized disease can be cured with surgery or radiation, whereas patients with 
high-risk or advanced disease have a poor prognosis. Although hormonal therapy in the 
form of medical or surgical castration can induce disease remissions even in these 
advanced cases, development of castration-resistant prostate cancer (CRPC) is 
eventually inevitable. In terms of treatment outcome, duration of the disease remission 
is critical for patient survival since therapeutic options for CRPC are limited and 
prognosis is poor, with a median survival of less than 2 years.
2-3
 However, there has 
been limited knowledge of pretreatment prognostic factors for clinical outcome of 
high-risk or advanced prostate cancer patients.
4-5
 Thus, there is an urgent need to 
establish new prognostic markers to aid in the prediction of unfavorable prognostic 
groups.  
E26 transformation-specific-1 (ETS-1), originally characterized as the v-ets 
retroviral gene, one of the two oncogenes (v-myb and v-ets) in the avian leukemia 
retrovirus E26, has been reported to play an important role in a variety of physiological 
and pathological processes, including embryogenesis, wound healing, and tumor 
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progression, attributed to their ability to regulate the expression of proteins involved in 
angiogenesis, invasion, and metastasis.
6-7
 It has been reported that ETS-1 is induced by 
some growth factor signals including vascular endothelial growth factor (VEGF) and 
both acidic and basic fibroblast growth factors (FGF)
8
 and activates transcription of 
various metastasis-, angiogenesis- and invasion-associated genes including matrix 
metalloproteinases (MMPs), urokinase-type plasminogen activator (uPA), and genes 
involved in energy metabolisms.
6,9
  
In fact, previous studies showed close associations between ETS-1 expression in 









 and ovarian cancers,
16
 indicating that 
ETS-1 expression is a useful marker for predicting metastasis and the outcome in 
patients with malignancies. In terms of prostate tumor, a recent report showed that 
ETS-1 could be a tumor marker for the differentiation of latent prostatic carcinoma from 
clinically significant disease.
17
 The authors observed significant increases in ETS-1 
expression along with progression through benign, and latent and clinical prostate 
cancers. They also reported that higher ETS-1 expression was associated with higher 
histological grade in both latent and clinical PC tissues. A more recent report 
also showed a significant correlation between ETS-1 expression and 
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histological grade of prosatte cancer.
18
 They also showed ETS-1 activation can promote 
castration-resistant progression of prostate cancer cells. However, clinical significance 
of ETS-1 expression among relatively advanced prostate cancers is yet to be elucidated. 
In the present study, we investigated the significance of ETS-1 expression in the 
prediction of treatment outcome of advanced prostate cancer patients.  
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Materials and Methods 
Samples of prostatic needle biopsy were obtained from 69 patients diagnosed to have 
PC at Kyoto University Hospital. Clinical charts of the 69 patients were reviewed for 
their clinicopathological characteristics and most of the cases had a metastatic or 
high-risk disease as evident in Table 1. This study was approved by the Institutional 
Review Board of Kyoto University Graduate School of Medicine (G-52) and all patients 
gave a written informed consent for the use of their tissue samples. 
There were 31 patients with metastatic disease, and 25 of them (the mean age at 
the time of biopsy was 74.6 ±
 
7.7 years) were available for followup data after androgen 
deprivation therapy (ADT). The 25 patients were additionally reviewed with regard to 
the time from the initiation of ADT to the development of CRPC, defined as three 
consecutive monthly increases in prostate-specific antigen (PSA) against hormonal 
therapy including antiandrogens.
14
 The patients were followed until 31 May 2009, at the 
median (range) of 69.6 (15 to 114) months. During this followup, 16 (64%) patients 
developed CRPC within 24 months, while the 9 (36%) were still responsive to ADT at 
the time of 24 months. 
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Paraffin-embedded sections of the prostate biopsy specimen from the 69 patients 
were examined with immunohistochemical (IHC) staining. Material handling and 
immunostaining were performed according to methods described previously.
17,19
 
Antigen retrieval was done with the microwave method. Briefly, citrate buffer (pH 6.0) 
was boiled for 10 min in a pressure-proof rice cooker (Rakuchin Gozen, Daiya, Tokyo, 
Japan) by microwave. Glass slides were put into a metal rack and boiled for another 20 
min in the rice cooker. Endogenous peroxidase activity was blocked by 0.3% H2O2 in 
methyl alcohol for 30 min. ETS-1 (C-20) affinity purified rabbit polyclonal antibody 
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA.) was used at a dilution of 1:500. 
We confirmed, using western blotting, that the antibody recognizes ETS-1 but not ERG, 
ETV1 or ETV4 (data not shown). After overnight incubation with primary antibody at 
4°C, samples were then incubated with biotinylated anti-rabbit immunoglobulin G 
(Vector Laboratories, Burlingame, CA, USA) diluted to 1:300 for 40 min. 
Avidin–biotin–peroxidase complex (ABC; ABC-Elite, Vector Laboratories) at a 
dilution of 1:100 was applied for 50 min. The coloring reaction was carried out with 0.3 
mg/mL of diaminobenzidine and 0.003% H2O2 and nuclei were counterstained with 
hematoxylin. For negative control, the primary antibody was omitted.  
The histopathological examination for ETS-1 expression and Gleason score was 
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performed by two of the authors (Y.S. and Y.M.) who were blinded to the 
clinicopathological data. ETS-1 expression levels were graded as 0, 1 and 2 based on 
staining intensity to represent from no staining to strong staining.  
The Pearson chi-square test or Fisher’s exact probability test was used to analyze 
the association between the expression of ETS-1 and Gleason score, tumor stage, 
patients’ age and PSA level as appropriate. All statistical analyses were performed using 
SPSS 16.0 software and P<0.05 was considered statistically significant.  
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Results 
IHC for ETS-1 demonstrated signals both in the nucleus and cytoplasm of prostatic 
tumor cells (Figure 1) but not in the adjacent benign tissues. There was a highly 
significant difference in the staining scores for ETS-1 among tumors at different clinical 
stage (P = 0.04; Table 2). Interestingly, 8 (89%) of 9 patients with score 2 were locally 
advanced or metastatic tumors. There was a statistically significant association among 
the staining scores for ETS-1 and the tumor’s Gleason sum (P = 0.03). There was no 
significant association of the staining scores for ETS-1 with PSA levels (P = 0.11) and 
age (P = 0.91).  
For the 25 patients with metastatic PC treated by ADT, there was a significant 
difference in the staining scores for ETS-1 between patients with and without rapid 
progression to CRPC within 24 months (P = 0.016; Table 3), but not in the Gleason sum 




In the present study IHC staining showed that ETS-1 expression was located to both 
nucleus and cytoplasm, which is consistent with previous reports.
10-12
 The reliability of 
immunohistochemistric techniques for the purpose to examine ETS-1 expression was 
supported by the well correlated results of in situ hybridization.
10-11
 These collectively 
indicate that IHC technique used in the present study is a reliable and reproducible 
method for evaluating the expression of functional ETS-1 protein.  
Using this technique, we have demonstrated that ETS-1 expression is associated 
with clinical stage and Gleason grade of PC. About 45% (13/29) of the PC with no 
ETS-1 expression (staining score 0) were clinically localized diseases, whereas 83% 
(33/40) of those with higher expression (staining score 1-2) were advanced (Table 2). 
Additionally, all cases except one (97%) of those with higher ETS-1 expression 
contained high-grade cancer component (Gleason score 7 or more). Our findings 
strongly suggest that ETS-1 expression is significantly associated with the aggressive 
biological features of PC, and therefore, associated with the adverse clinicopathological 
characteristics of PC.  
Additionally, we have shown that ETS-1 expression is significantly associated 
with the rapid castration-resistant progression of PC after androgen deprivation therapy. 
12/23 
This is consistent with a previous report by Smith et al.
18
 showing that ETS-1 activation 
led prostate cancer cells to castration-resistant status. Our results suggest that ETS-1 
expression can be a useful predictor for treatment outcome of the patients with 
advanced prostate cancer. A major clinical problem with hormonal therapy of advanced 
PC is the pretreatment prediction of time to castration-resistant progression.  
Recently, Sim et al.
20
 reported that failure to attain a nadir PSA of < 1 ng/mL 
after treatment was the most important predictor of time to CRPC and a nadir PSA of > 
2 ng/mL was a risk factor for poor overall survival. However, those findings will be 
obtained only after treatment has been initiated, and as the authors reported, prediction 
of treatment outcome at pretreatment settings was difficult since the biopsy Gleason 
score or initial PSA level was not a predictor of rapid progression to CRPC. Indeed, the 
biopsy Gleason score and initial PSA level failed to predict time to progression to 
CRPC in the present study, too. In this regard, a significant association between 
increased ETS-1 expression and a shorter time to be CRPC observed in this study would 
enable us to separate those patients who are likely to fail on hormone therapy from 
those who are more likely to achieve long term stable disease at pretreatment settings. 
This is an important prospect, which should be validated with a larger study in the 
future.   
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Aberrant activation of Ets family transcription factors by gene fusion with 
certain androgen-dependent genes is a frequently observed alteration inducing invasion 
of prostate cancer cells,
21-22





events in the natural history of PC. Considering that Ets family transcription factors 
share a number of target genes, ETS-1 is likely to play an important role in prostate 
cancer. Indeed, a number of genes that can facilitate cancer progression are known as 
transcriptional target of ETS-1.
6,9
 Additionally, ETS-1 has been reported to activate 
transcription of Sp1 resulting in an increase in lipogenesis and cell proliferation through 
induction of fatty acid synthase,
25
 which is thought to be associated with 
castration-resistant progression of PC.
26
   
We recognize that this study has a limitation of the relatively few patients, 
although other strengths were comprehensive data collection, analysis by a central 
pathologist and a reasonable duration of follow-up, which helped to compensate for the 
small samples. Prospective validation studies on ETS-1 expression together with other 
molecular markers are warranted in the future. Using biopsy tissue can be problematic 
as tumor often shows heterogeneity. However, clinical decision-making should be often 
made based on biopsy specimen. As it has been reported previously that the antibody 
used in this study can cross-react with Annexin V, an unrelated protein.
27
 Although we 
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cannot exclude strictly the possibility that the antibody recognize unrelated protein, 
ETS-1 expression evaluated with the antibody still has diagnostic significance in 
predicting time to castration-resistant progression.  
In conclusion, immunohistochemical analysis of PC specimens clearly 
demonstrated that the expression of ETS-1 was associated with pathological grade and 
clinical stage of the disease. Importantly, we found that ETS-1 expression was 
significantly associated with time to CRPC in patients with advanced PC. Although 
further systematic studies are necessary, these findings support the possibility that the 
higher expression of ETS-1 can play an important role in the poor differentiation of PC 
cells. Thus, ETS-1 may be a useful marker for the risk of PC progression. 
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Figure 1. Immunohistochemistry of ETS-1 in prostatic carcinomas. It should be noted 
that heterogeneous expression of ETS-1 is observed both in the cytoplasm and 
the nucleus of the tumor cells. (a) No staining (staining score 0). (b) Weak 
staining (staining score 1). (c) Strong staining (staining score 2). (d) Negative 




Table 1 Clinicopathological characteristics of the 69 prostate cancer patients 
Variable Median (range) or N (%)  
Age (years) 72.4 (54-92) 
≤70 27 (39.1%) 
>70 42 (60.9%) 
Clinical stage   
Localized 20 (29.0%) 
Locally advanced 18 (26.1%) 
Metastatic 31 (44.9%) 
Gleason score  
6 or less 8 (11.6%) 
7 32 (46.4%) 
8-10 29 (42.0%) 
Initial PSA (ng/ml) 426.9 (4.2-13000) 
<10 18 (26.1%) 
10-20 14 (20.3%) 











ETS-1 expression (score) 
P value* 0 (%) 
(n = 29) 
1 (%) 
(n = 31) 
2 (%) 
(n = 9) 
Clinical stage
 
     
Localized 20  13 (65) 6 (30) 1 (5) 
P = 0.04 Locally advanced 18 8 (44) 6 (33) 4 (22) 
Metastatic 31 8 (26) 19 (61) 4 (13) 
Gleason score      
6 or less 8  7 (88) 1 (12) 0 (0) 
P = 0.03 7 32  17 (53) 11 (34) 4 (13) 
8-10 29  5 (17) 19 (66) 5 (17) 
Age (years)      
≤70 27 12 (44) 12 (44) 3 (11) 
P = 0.91 
>70 42 17 (40) 19 (45) 6 (14) 
Initial PSA (ng/ml)       
<10 18  8 (44) 8 (44) 2 (11) 
P = 0.11 10-20 14  9 (64) 2 (14) 3 (21) 
>20 37  12 (32) 21 (57) 4 (11) 
* Chi-square test
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Table 3. Association between ETS-1 expression and the time to be CRPC in 25 
metastatic prostate cancer patients treated by ADT.  
Variable Number of cases 
Time to be CRPC 
P value* >24 months 
(n = 9) 
<24 months 
(n = 16) 
ETS-1 expression (score)      
0 10 7 3 
P = 0.016 1 11 2 9 
2 4 0 4 
Gleason score     
6 or less 2 2 0 
P = 0.225 7 8 2 6 
8-10 15 5 10 
Initial PSA (ng/ml)      
<500 19 8 11 
P = 0.364** 
>500 6 1 5 
* Chi-square test, **Fisher’s exact test 
 
